Arbutus Biopharma
ABUS
ABUS
50 hedge funds and large institutions have $91.9M invested in Arbutus Biopharma in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 21 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
43% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 21
47% less capital invested
Capital invested by funds: $173M → $91.9M (-$80.9M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
50
Holding in Top 10
–
Calls
$1.05M
Puts
$683K
Top Buyers
| 1 | +$6.67M | |
| 2 | +$1.45M | |
| 3 | +$261K | |
| 4 |
JPMorgan Chase & Co
New York
|
+$223K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$180K |
Top Sellers
| 1 | -$80.9M | |
| 2 | -$2.48M | |
| 3 | -$796K | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$592K |
| 5 |
Morgan Stanley
New York
|
-$573K |